The drug ABEVMY contains one active pharmaceutical ingredient (API):
Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Estonia Ireland Lithuania New Zealand Poland Tunisia South Africa
This drug has been assigned below unique identifiers within the countries it is being marketed: